Literature DB >> 18460940

The role of mullerian inhibiting substance in female reproduction.

Gary S Nakhuda1.   

Abstract

PURPOSE OF REVIEW: To review the role of mullerian inhibiting substance in the context of female reproduction. RECENT
FINDINGS: Serum and follicular fluid mullerian inhibiting substance can be measured by commercially available enzyme-linked immunosorbent assay kits. Mullerian inhibiting substance is secreted from small antral follicles with minimal fluctuation throughout the menstrual cycle. The exact biological functions of mullerian inhibiting substance are uncertain; however, mullerian inhibiting substance most likely mediates follicle recruitment and selection, and may inhibit aromatase activity. Most data suggests an interaction between follicle-stimulating hormone, and mullerian inhibiting substance although the exact nature of the relationship is unknown. Mullerian inhibiting substance is characteristically elevated in polycystic ovarian syndrome, and may be associated with other features of polycystic ovary syndrome such as insulin resistance, hyperandrogenemia, and the degree of anovulation. Mullerian inhibiting substance changes have also been associated with functional hypothalamic amenorrhea, premature ovarian failure, endometriosis and obesity. Mullerian inhibiting substance has been studied extensively in the context of in-vitro fertilization and has been correlated with several outcome parameters.
SUMMARY: Mullerian inhibiting substance is gaining acceptance as a useful marker of female reproductive function, especially with ovulatory disorders and IVF outcomes. Mullerian inhibiting substance offers several advantages to existing screening tests, but establishment of an assay standard should be considered before widespread clinical implementation becomes viable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18460940     DOI: 10.1097/GCO.0b013e3282fe99f2

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  9 in total

1.  Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.

Authors:  Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Louise A Brinton; Brian L Egleston; Roni Falk; Renée T Fortner; Kathy J Helzlsouer; Annika Idahl; Rudolph Kaaks; Eva Lundin; Melissa Merritt; Charlotte Onland-Moret; Sabina Rinaldi; María-José Sánchez; Sabina Sieri; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley Tworoger; Kala Visvanathan; Vittorio Krogh; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Wei Zheng; Joanne F Dorgan
Journal:  Fertil Steril       Date:  2017-04       Impact factor: 7.329

2.  Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy.

Authors:  Bo Yu; Nataki Douglas; Michel J Ferin; Gary S Nakhuda; Katherine Crew; Rogerio A Lobo; Dawn L Hershman
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

3.  Anti-mullerian hormone and cumulative pregnancy outcome in in-vitro fertilization.

Authors:  Suresh Kini; H W Raymond Li; Dave Morrell; Sue Pickering; K Joo Thong
Journal:  J Assist Reprod Genet       Date:  2010-05-14       Impact factor: 3.412

4.  Bariatric Surgery Reduces Serum Anti-mullerian Hormone Levels in Obese Women With and Without Polycystic Ovarian Syndrome.

Authors:  Francesco Chiofalo; Cristina Ciuoli; Caterina Formichi; Federico Selmi; Raffaella Forleo; Ornella Neri; Giuseppe Vuolo; Patrizia Paffetti; Furio Pacini
Journal:  Obes Surg       Date:  2017-07       Impact factor: 4.129

5.  Early Life Body Fatness, Serum Anti-Müllerian Hormone, and Breast Density in Young Adult Women.

Authors:  Kimberly A Bertrand; Heather J Baer; E John Orav; Catherine Klifa; Ajay Kumar; Nola M Hylton; Erin S LeBlanc; Linda G Snetselaar; Linda Van Horn; Joanne F Dorgan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-09       Impact factor: 4.254

6.  Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian-inhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells.

Authors:  Peter J Malloy; Lihong Peng; Jining Wang; David Feldman
Journal:  Endocrinology       Date:  2008-12-04       Impact factor: 4.736

7.  Determining an anti-Mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve.

Authors:  Zaher Merhi; Athena Zapantis; Dara S Berger; Sangita K Jindal
Journal:  J Assist Reprod Genet       Date:  2013-08-21       Impact factor: 3.412

8.  Serum Müllerian inhibiting substance levels are lower in premenopausal women with breast precancer and cancer.

Authors:  Andrew C McCoy; Beth Kliethermes; Ke Zhang; Wenyi Qin; Robert Sticca; Michael Bouton; Edward R Sauter
Journal:  BMC Res Notes       Date:  2011-05-26

9.  Serum anti-Müllerian hormone level as a predictor of poor ovarian response in in vitro fertilization patients.

Authors:  Sezai Sahmay; Meral Cetin; Pelin Ocal; Semih Kaleli; Hulya Senol; Fatih Birol; Tulay Irez
Journal:  Reprod Med Biol       Date:  2010-09-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.